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Abstract
Background: Research on Juvenile Idiopathic Arthritis (JIA) should support patients, caregivers/parents (carers) and
clinicians to make important decisions in the consulting room and eventually to improve the lives of patients with
JIA. Thus far these end-users of JIA-research have rarely been involved in the prioritisation of future research.
Main body: Dutch organisations of patients, carers and clinicians will collaboratively develop a research agenda for
JIA, following the James Lind Alliance (JLA) methodology. In a ‘Priority Setting Partnership’ (PSP), they will gradually
establish a top 10 list of the most important unanswered research questions for JIA. In this process the input from
clinicians, patients and their carers will be equally valued. Additionally, focus groups will be organised to involve
young people with JIA. The involvement of all contributors will be monitored and evaluated. In this manner, the
project will contribute to the growing body of literature on how to involve young people in agenda setting in a
meaningful way.
Conclusion: A JIA research agenda established through the JLA method and thus co-created by patients, carers
and clinicians will inform researchers and research funders about the most important research questions for JIA.
This will lead to research that really matters.
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Background
Research priority setting involving the end-users of
knowledge is clearly needed in order to formulate re-
search questions that can really make a difference [1–3].
In a recent review, Odgers et al. reported a substantial
increase in the number of research priority setting
initiatives in paediatric chronic disease since 2010, gen-
erating a broad range of priorities shared across multiple
conditions [4]. Unfortunately, the methodology was gen-
erally inadequately described. This lack of clarity raises
concerns over the legitimacy and relevance of identified
priorities. Odgers et al. suggested that the available sys-
tematic methods of priority setting should be used more
often [4].
Patient and parent/caregiver (carer) involvement in
establishing research priorities is crucial in generating
a research agenda that encompasses the full spectrum
of issues that affects paediatric patients with chronic
* Correspondence: C.G.Schoemaker-3@umcutrecht.nl
1Pediatric Rheumatology and Immunology, Wilhelmina Children’s Hospital,
University Medical Center Utrecht, Utrecht, Netherlands
2Netherlands JIA Patient and Parent Organisation, member of ENCA,
Amsterdam, The Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Schoemaker et al. Pediatric Rheumatology  (2018) 16:57 
https://doi.org/10.1186/s12969-018-0276-3
disease [5–9]. Thus far, their involvement in research pri-
ority appears to be limited. Only approximately one-in-four
studies reported some parental/caregiver involvement, and
only 5% involved children directly [4]. Furthermore, quali-
tative research showed that the involvement of patients and
carers seems to be challenging: real co-design does not hap-
pen by itself [3]. Therefore, precautionary measures need to
be taken to empower patients and carers [7], and their
involvement in the process should be monitored and
evaluated [4, 10].
As noted above, understanding young people’s research
priorities is crucial to develop research that is in tune with
their needs [4, 11, 12]. However, some researchers have re-
ported challenges to collaborating with young people in
health research [12–14]. More recently, there appears to
be increasing efforts to involve children and adolescents
in research priority setting [7, 11, 12, 15]. Parsons et al.
organised 13 focus groups involving young people with
rheumatic diseases, aged 11–24, to explore what they be-
lieved to be important research questions regarding their
condition [12, 16]. They provided evidence that even
younger adolescents (11–15 years) are equipped to discuss
and prioritise scientific research even if they are relatively
research naive [16].
In 2018 four Dutch organisations of patients, parents
and clinicians will start to establish a research agenda for
Juvenile Idiopathic Arthritis (JIA). The research agenda
was initiated by the Netherlands JIA patient and parent
organisation (Dutch Juvenile Arthritis Association: DJAA),
a member organisation of the European Network for Chil-
dren with Arthritis (ENCA). Three other Dutch organisa-
tions are involved: the Dutch network organisation for
young arthritis patients (16–30 years old) Youth-R-
Well.com, the Dutch Association for Pediatric Rheuma-
tology (DAPR) and the Dutch Health Professionals in
Pediatric Rheumatology (DHPPR). The project will be
based at the Pediatric Rheumatology and Immunology
department of the Wilhelmina Children’s Hospital (WKZ)
in Utrecht. DAPR, DJAA and WKZ funded the project.
Amsterdam UMC will develop and lead the focus groups
for young people with JIA, and enable them to have effect-
ive and fulfilling participation in the whole process.
PGO-support, a Dutch networking organisation for pa-
tient organisations will issue an independent process
evaluation of the PSP. The Department of Medical Ethics
at the Julius Center of the UMC Utrecht will perform the
research concerning the process evaluation.
In this paper, the project is outlined briefly. We discuss
how we will address the aforementioned questions on
the use of systematic methods and the feasibility of
meaningful patient and caregiver participation in re-
search agenda setting. Formulating a research agenda is
not a goal in itself [2, 17]. Finally, we will describe how
we aim to inspire researchers and research funders by
the defined priorities when preparing for and guiding
funding new research projects.
Main text
In a recent review on patient and public engagement in
priority setting, Manafo et al. described four highly
structured deliberative methods that are inclusive and
objectively based, specific to the priorities of all stake-
holders engaged in the process [5]. Two of these methods
have successfully been applied in the Netherlands: The
Dialogue Method and the James Lind Alliance (JLA) Pri-
ority Setting Partnerships [18, 19]. Both methods are
clearly suited for this purpose [5, 20]. Eventually, we chose
the JLA method as it proved to be very effective in imple-
menting agendas in calls for research. United Kingdom’s
National Institute for Health Research (NIHR) and several
funding charities, for example Marie Curie, the Multiple
Sclerosis Society and Parkinson’s UK, have adopted the re-
search agendas as an important part of their research
funding strategy [21].
The James Lind Alliance (JLA) is a non-profit initiative
established in the United Kingdom (UK) in 2004 by Sir
Iain Chalmers [22]. The JLA team is positioned at the
NIHR Evaluation, Trials and Studies Coordinating
Centre (NETSCC), based at the University of Southamp-
ton in the UK. The goal of the JLA is to bring together
the end users of scientific knowledge – patients, carers
and clinicians – to jointly formulate a research agenda
for a disease or type of care. In a so-called ‘Priority Set-
ting Partnership’ (PSP) they gradually establish a top-10
list of the most important unanswered questions for
their health area of interest [23].
Until now about 70 different Top 10s have been pub-
lished. More information on the content and the back-
ground of these Top 10s can be found on the JLA
website [24]. In 2015, Chalmers and colleagues com-
pared the prioritised unanswered questions of several
PSPs to the research questions they found in registered
clinical trials. They demonstrated that the JLA method
identifies questions and themes that are not yet being
addressed in current studies [2].
The JLA method consists of 5 steps: setting up the
steering group, gathering uncertainties, data processing
and verifying uncertainties, interim priority setting, and
final priority setting (see Table 1). In a free internet-based
Guidebook the JLA method has been described in more
detail [23]. Following these five steps, it takes approxi-
mately twelve to eighteen months to formulate a research
agenda [23].
A PSP is led by a steering group (10–15 people) that
coordinates the PSP and organises the activities [23].
The Dutch JIA-PSP steering group will be led by a carer
and a pediatric rheumatologist. The steering group will in-
clude representatives of patients (i.c. adult JIA-patients),
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carers (i.c. parents) and clinicians (i.c. pediatric rheumatol-
ogists, ophthalmologists, physiotherapists and nurses,).
The four previously mentioned organisations recruited
their members for the steering group. Four groups –
pediatric rheumatologists, other health professionals, pa-
tients and parents – will be equally represented in the
steering group. The two PSP Leaders made a selection for
the pediatric rheumatologists, and invited one of the cen-
ters to invite one of their nurse practitioners, in order to
achieve a balanced representation of clinicians of all 6 aca-
demic centres including their affiliated rehabilitation
centre within the steering group. These decisions were
made in collaboration with the chairs of both organisa-
tions. Furthermore, all Dutch centers for pediatric rheu-
matology will be represented in this steering group. A MD
PhD-student coordinates the JIA-PSP, reviews the data
collected, identifies the existing research evidence, and
formulates potential research questions with input from
the steering group. The PSP will be supported and guided
by a trained JLA Adviser [23].
According to Odgers et al., the JLA approach may not
be very well suited to children with chronic disease [4].
It demands creative and developmentally appropriate
strategies to empower children to reflect on their situ-
ation, and how research could benefit them and to ar-
ticulate their priorities [25, 26]. Inspired by the work of
Parsons et al. we will organise additional focus group
meetings involving children and adolescents with JIA.
This established qualitative method allows the partici-
pants to draw from other participant’s knowledge and al-
lows for a conversation among peers [25].
Specific themes and research questions formulated by
these young patients will be added to our dataset of un-
certainties from the survey. In the focus groups the
young patients will discuss how they wish to be involved
in the process and which arrangements need to be made
in order for them to participate successfully. The results
of the focus group will be discussed in the second meet-
ing of the steering group. This may change the involve-
ment of young patients in the process onwards.
Some precautionary measures to empower patients and
carers are built into the JLA method. Patients and carers
take part in the steering group. We will ensure that the
chairing of the steering group is fair and neutral so as not
to favour one group over another. The final priority set-
ting workshop of the PSP is attended by patients and
carers as well as clinicians and the opinions of all people
at the workshop are valued equally [23]. The JLA supports
an adapted Nominal Group Technique for PSPs choosing
their priorities during the final workshop. One benefit of
this technique is that it prevents the domination of dis-
cussion by a single person and encourages the partici-
pation of less assertive members. There is no hierarchy
between the different participants; no one individual or
group’s views or experiences are more valid than an-
other’s. Nominal Group Technique is a well-established
and well-documented approach to decision making.
Despite these measures, engaging patients and carers in
the complexities of health science based discussions of
uncertainty is challenging [27]. To empower patients
and carers in the steering group, most of them received
a two-day training as a patient partner in research [28].
Table 1 The priority setting process in the James Lind Alliance methodology
Step in the process Description
1. Setting up the steering group A PSP is led by a steering group that coordinates the PSP and organises the
activities. It will include representatives of patients, carers and clinicians.
2. Gathering uncertainties An electronic survey questionnaire is distributed widely. Patients, carers and
clinicians will be asked: “What questions would you like answered to improve
the health and wellbeing of people with JIA?” For young people with JIA focus
groups will be organised. Research recommendations stated in systematic reviews
and clinical guidelines are searched for as well (i.c. the Dutch JIA-medication
guideline and the European SHARE initiative).
3. Data processing and verifying uncertainties Out-of-scope submissions are removed. The eligible submissions are categorised
and rephrased as researchable questions. Duplicates and very similar submissions
are combined. Questions that have already been answered in relevant good quality
research will be removed.
4. Interim priority setting The long list of in-scope verified uncertainties goes into an electronic interim priority
setting survey. Patients, carers and clinicians are asked to choose (and possibly also
rank) the 10 uncertainties from the list that are most important in their experience.
Completed interim prioritisation results are grouped into patients, carers and clinicians,
and separate scores kept to ensure fair weighting of the constituent groups. The top
25–30 questions are taken to the final workshop.
5. Final priority setting In a final day-long workshop, 20–30 people (patients, carers and clinicians) discuss the
questions and gradually agree on the final order of priority of the list, focusing especially
on agreeing a ‘Top 10’. The Top 10 will be published on the JLA website, and in a peer
reviewed journal.
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A process evaluation with a specific focus on the eth-
ical aspects of the decision-making process is conducted
parallel to the priority setting process [10, 27]. In the
process evaluation, issued by PGOsupport and executed
by a researcher from the Julius Center, attention will be
paid to the inclusion of different stakeholders, their in-
fluence on the priority setting as well as facilitating and
limiting factors for equal deliberation between the differ-
ent stakeholders. For this, the researcher from the Julius
Center will observe all key meetings during the project
and perform additional interviews among the stake-
holder groups. Important deliverables include evaluation
of the suitability of the JLA method for patient organisa-
tions that aim to take a role as partner and/or driving
force in scientific research; identification of critical suc-
cess factors during the process in relation to patient rep-
resentation; identification of specific requirements for
appropriate involvement of children and adolescents.
PGOsupport will disseminate the results of the evalu-
ation via the relevant media in order to inform other pa-
tient organisations that consider a similar approach.
Formulating a research agenda for JIA is not a goal in
itself. It is important that researchers and research fun-
ders are inspired by the defined priorities when prepar-
ing for and funding new research projects. Therefore all
Dutch academic centers for pediatric rheumatology will
be represented in the steering group. We will present
our results at a 2019 meeting of a large Dutch/Canadian
research project on personalised medicine, UCAN
CAN-DU, funded by the Netherlands Organisation for
Health Research and Development ZONMW, the Can-
adian Institutes of Health Research (CIHR) and Dutch
Arthritis Foundation (ReumaNederland), to inspire fur-
ther JIA-research. Funding agencies will be invited for
our final workshop. Members and ambassadors of the
Dutch JIA-PSP are involved in European organisations
like ENCA, Paediatric Rheumatology European Society
(PReS) and the European League Against Rheumatism
(EULAR). Collectively, these measures will ensure the
optimal implementation of the research agenda in dif-
ferent “layers” of research.
Conclusions
In 2018 four Dutch organisations for JIA-patients, par-
ents, pediatric rheumatologists and health profes-
sionals will initiate a PSP for JIA, following the JLA
methodology. This research agenda, will be established
in 2019, and will improve the relevance of JIA-research
in the Netherlands and beyond. This will not only
benefit patients, parents and clinicians in the consult-
ing room, but also the JIA-researchers themselves
since their research will really matter to the people
that need it most.
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